Media Category: Immunology

In this keynote delivered in Athens, Professor Carlo Pozzilli takes the audience through the past, present and future of anti-CD20 therapies in multiple sclerosis. Starting from the early interferon era and the first monoclonal antibodies, Professor Pozzilli retraces how B-cell depletion moved from a provocative concept to a central pillar of MS management. Drawing on pivotal trials, 10-year extension data and real-world evidence, the discussion adresses why starting high-efficacy therapy early matters, how anti-CD20 agents compare with other high-efficacy options such as natalizumab,...

Inflammation is the driving force in the pathogenesis of MS. Over the past decades, we can observe increased recognition that various immune cells are involved: [CD4+ Tc, CD8+ Tc, macrophages] plus Bc plus microglia. As a consequence of gained knowledge in the immunopathogenesis of MS -> DMTs are, thus, increasingly developed towards targeted treatments (at the right time of the disease course…).  BIOGRAPHY THOMAS BERGER Prof. Thomas Berger, MD, MSc, FEAN, is Professor of Neurology and Chair of the Dept. of Neurology as well as Chair of the...